The objectives of toxicokinetic (TK) studies are to evaluate systemic exposure of the toxicity species to drug and/or metabolite(s) and to relate exposure to dose level and toxicological findings. The tacit assumption is that such exposure can be related to target organ toxicity. Planning a TK program involves early development (often during discovery support) of an appropriate plasma assay, assurance that the studies conform to Good Laboratory Practices, evaluating exposure at steady state, and effective collaboration among toxicologists, kineticists, and other relevant disciplines. The 3 types of TK studies-prospective, concomitant, and retrospective-each have different goals. The various stages of TK program implementation range from those during drug discovery and selection to support of chronic toxicity studies. Exposure is best expressed as the area under the plasma concentration/time curve of drug and/or metabolite(s) and, for highly protein bound drugs, is based on the unbound fraction. Although the objectives of TK programs are generally standard and the Second International Conference on Harmonization has developed TK guidelines, the programs differ among pharmaceutical companies. Some variables in program design and implementation include properties of the drug, formulation used, characteristics of the target species, ability to develop a toxicokinetictoxicodynamic relationship, strategies based on scientific/technical/philosophical considerations, dedicated resources, corporate support, and effectiveness of interdepartmental collaborations.
Bode G. (1994). Toxicokinetics in long-term toxicity and carcinogenicity studies. Drug Inform. J. 28: 213-220.
4.
Caldwell J. (1992). Problems and opportunities in toxicity testing arising from species differences in xenobiotic metabolism. Toxicol. Lett. 64: 651-659.
5.
Carey PK and Spurling NW (1994). Maximum tolerated dose studies. Drug Inform. J. 28: 203-211.
6.
Case D. (1994). Toxicokinetics: Some definitions. Drug Inform. J. 28: 145-149.
7.
Cayen MN (1987). Retrospective evaluation of appropriate animal models based on metabolism studies in man. In: Human Risk Assessment-The Role of Animal Selection and Extrapolation, MV Roloff (ed). Taylor & Francis, New York, pp. 99-112.
8.
Cayen MN (1993). Development of stereoisomeric drugs: An industrial perspective. In: Drug Stereochemistry. Analytical Methods and Pharmacology, 2nd ed., IW Wainer (ed). Marcel Dekker, New York, pp. 399-410.
9.
Cayen MN and Black HE (1993). Role of toxicokinetics in dose selection for carcinogenicity studies. In: Drug Toxicokinetics, PG Welling and FA de la Iglesia (eds). Marcel Dekker, New York, pp. 69-83.
10.
Chasseaud LF (1992). The importance of pharmacokinetic/toxicokinetic and metabolic information in carcinogenicity study design. Drug Inform. J. 26: 445-455.
11.
Chasseaud LF (1993). Role of toxicokinetics in toxicity testing. In: Drug Toxicokinetics, PG Welling and FA de la Iglesia (eds). Marcel Dekker, New York, pp. 105-142.
12.
Chiu SL, Thompson K., Vincent S., Alvaro R., Huskey S., Steams R., and Pettibone D. (1994). The role of drug metabolism in drug discovery: A case study in the selection of an oxytocin receptor antagonist for development . Toxicol. Pathol. 23: 124-130.
13.
Clark B. and Smith DA (1984). Pharmacokinetics and toxicity testing. CRC Crit. Rev. Toxicol. 12: 343-385.
14.
Dahlem AM, Allerheiligen SR, and Vodicnik MJ (1994). Concomitant toxicokinetics: Techniques for and interpretation of exposure data obtained during the conduct of toxicology studies. Toxicol. Pathol. 23: 170-178.
15.
Dayan AD (1994). What use is toxicokinetics? Drug Inform. J. 28: 143-144.
16.
de la Iglesia F. and Greaves P. (1989). Role of toxicokinetics in drug safety evaluations. In: Toxicokinetics and New Drug Development, A Yacobi, JP Skelly, and VK Batra (eds). Pergamon Press, New York, pp. 21-32.
17.
Draft Tripartite Guideline, International Conference on Harmonization (ICH-2) (1993). Carcinogenicity: Guidance for Dose Selection for Carcinogenicity Studies of Therapeutics.
18.
Draft Tripartite Guideline, International Conference on Harmonization (ICH-2) (1993). Toxicokinetics: The Assessment of Systemic Exposure in Toxicity Studies.
19.
Garattini S. (1994). Contributions of toxicokinetics to toxicology of drugs. Drug Inform. J. 28: 255-258.
20.
Glocklin VC and Chah CC (1989). Toxicokinetics in preclinical evaluation of drug safety. In: Toxicokinetics and New Drug Development, A Yacobi, JP Skelly, and VK Batra (eds). Pergamon Press, New York, pp. 33-41.
21.
Green T. (1990). Changes in metabolism during toxicity tests. Xenobiotica20: 1233-1240.
22.
Halperin-Walega E., Yacobi A., and Batra VK (1993). Toxicokinetic study design and integrated programs. In: Drug Toxicokinetics, PG Welling and FA de la Iglesia (eds). Marcel Dekker , New York , pp. 85-104.
23.
Heykants J. and Meuldermans W. (1994). Nonclinical kinetics and metabolism studies in support of the safety assessment of drugs. Drug Inform. J . 28: 163-172.
24.
Humphrey MJ and Smith DA (1992). Role of metabolism and pharmacokinetic studies in the discovery of new drugs-Present and future perspectives. Xenobiotica22: 743-755.
25.
Igarashi T. (1994). The use and abuse of toxicokinetics: What does actual data tell researchers? Drug Inform. J. 28: 285-293.
26.
Jochemsen R. , Bazot D., Brillanceau MH, and Lupart M. (1993). Assessment of drug exposure in rat dietary studies. Xenobiotica23: 1145-1154.
27.
Johnson R., Christensen J., and Lin C-C. (1994). Sensitive gas-liquid chromatographic method for the determination of loratadine and its major active metabolite, descarboethoxyloratadine, in human plasma using a nitrogen-phosphorus detector. J. Chromatog . B657: 125-131.
28.
Kato R., Case DE, Hakusui H., Noda K., Sagami F., Horii I., Mayahara H., Cayen MN, Marriott MB, and Igarashi T. (1993). Toxicokinetics: Its significance and practical problems. J. Toxicol. Sci. 18: 211-238.
29.
Matula TI, Voith K., and Franklin CA (1994). Toxicokinetics-A regulatory viewpoint in Canada . Drug Inform. J. 28: 159-162.
30.
Miwa GT (1994). Goals, designs, timing and future opportunities for nonclinical drug metabolism studies. Toxicol. Pathol. 23: 131-135.
31.
Monro A. (1993). The paradoxical lack of interspecies correlation between plasma concentrations and chemical carcinogenicity. Reg. Toxicol. Pharmacol. 18: 115-135.
32.
Monro A. (1994). Toxicokinetics: What one can and cannot do with plasma concentrations. Drug Inform. J. 28: 259-262.
33.
Nedelman JR , Gibiansky E., Tse FLS , and Babiuk C. (1993). Assessing drug exposure in rodent toxicity studies without satellite animals . J. Pharmacokin. Biopharmaceutics21: 323-334.
34.
Nimmo WS and Watson N. (1994). What a clinical pharmacologist requires from toxicokinetic studies. Drug Inform. J. 28: 185-186.
35.
Pelkonen O. (1994). The role of toxicokinetics in developmental toxiciy testing: Lessons from comparative developmental drug metabolism. Drug Inform. J. 28: 225-234.
36.
Rauws AG and Groen KG (1994). Future perspectives of toxicokinetics: A regulator's view. Drug Inform. J. 28: 295-300.
37.
Shah VPMidha KK, Dighe S., McGilveray IJSkelly JP, Yacobi A., Layloff T., Viswanathan CT, Cook CE, McDowall RD, Pittman KA and Spector S. (1992). Analytical methods validation: Bioavailability, bio-equivalence, and pharmacokinetic studies. J. Pharmacol. Sci. 81: 309-312.
38.
Shindo A. (1994). What is required from toxicokinetic studies? The viewpoint of Japanese kineticists. Drug Inform. J. 28 : 173-183.
39.
Sjoberg P. (1994). Toxicokinetics in preclinical safety assessment- Views of the Swedish Medical Products Agency. Drug Inform. J. 28: 151-157.
40.
Smith DA, Humphrey MJ, and Charuel C. (1990). Design of toxicokinetic studies. Xenobiotica20: 1187-1199.
41.
Smith RL (1988). The role of metabolism and disposition studies in the safety assessment of pharmaceuticals. Xenobiotica18 (suppl1): 89-96.
42.
Takacs AR (1994). Ancillary approaches to toxicokinetic evaluations . Toxicol. Pathol. 23: 179-186.
43.
Voisin EM, Ruthsatz M., Collins JM, and Hoyle PC (1990). Extrapolation of animal toxicity to humans: Interspecies comparisons in drug development. Regul. Toxicol. Pharmacol . 12: 107-116.
44.
Warrander A. (1994). Around the world with 80+ companies-A review of toxicokinetic practices. Drug Inform. J. 28: 281-283.
45.
Weisburger JH (1994). Does the Delaney Clause of the U.S. food and drug laws prevent human cancers? Fund. Appl. Toxicol. 22: 483-493.
46.
Wright DS (1993). Analytical method considerations for toxicokinetic studies. In: Drug Toxicokinetics, PG Welling and FA de la Iglesia (eds). Marcel Dekker, New York, pp. 1-18.
47.
Wrighton SA , Ring BJ, and VandenBranden M. (1994). The use of in vitro metabolism techniques in the planning and interpretation of drug safety studies. Toxicol. Pathol. 23: 199-208.
48.
Zbinden G. (1988). Biopharmaceutical studies, a key to better toxicology . Xenobiotica18(suppl.1): 9-14.
